Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Calcium phosphate nanoparticle adjuvant.

He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJ.

Clin Diagn Lab Immunol. 2000 Nov;7(6):899-903.

2.

Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.

He Q, Mitchell A, Morcol T, Bell SJ.

Clin Diagn Lab Immunol. 2002 Sep;9(5):1021-4.

3.

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH.

Vaccine. 2012 Oct 12;30(46):6541-50. doi: 10.1016/j.vaccine.2012.08.049. Epub 2012 Sep 1.

4.

Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.

Khodai T, Chappell D, Christy C, Cockle P, Eyles J, Hammond D, Gore K, McCluskie MJ, Evans DM, Lang S, Loudon PT, Townend T, Wright P, West K, Bright H.

Clin Vaccine Immunol. 2011 Oct;18(10):1702-9. doi: 10.1128/CVI.05071-11. Epub 2011 Aug 18.

5.
6.
7.

Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.

Wizel B, Persson J, Thörn K, Nagy E, Harandi AM.

Vaccine. 2012 Jun 19;30(29):4361-8. doi: 10.1016/j.vaccine.2012.02.019.

PMID:
22682292
8.

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.

Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL.

J Immunol. 2001 Mar 1;166(5):3451-7.

9.
10.

Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.

Berman PW, Gregory T, Crase D, Lasky LA.

Science. 1985 Mar 22;227(4693):1490-2.

PMID:
2983428
11.

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine.

Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G.

J Infect Dis. 1994 Nov;170(5):1110-9.

PMID:
7963702
12.

Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, Cohen JI, Straus SE.

J Virol. 2005 Jan;79(1):410-8. Erratum in: J Virol. 2005 Apr;79(7):4554.

13.

Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.

Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI.

J Infect Dis. 2009 Oct 1;200(7):1088-95. doi: 10.1086/605645.

14.
15.

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, Montomoli E, Del Giudice G, Rappuoli R, O'Hagan DT.

Vaccine. 2008 Jan 24;26(4):552-61. Epub 2007 Dec 7.

PMID:
18162266
16.
17.

An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.

Skoberne M, Cardin R, Lee A, Kazimirova A, Zielinski V, Garvie D, Lundberg A, Larson S, Bravo FJ, Bernstein DI, Flechtner JB, Long D.

J Virol. 2013 Apr;87(7):3930-42. doi: 10.1128/JVI.02745-12. Epub 2013 Jan 30.

18.

Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.

Awasthi S, Huang J, Shaw C, Friedman HM.

J Virol. 2014 Aug;88(15):8421-32. doi: 10.1128/JVI.01130-14. Epub 2014 May 14.

20.

Supplemental Content

Support Center